Catalytic enantioselective amide allylation of isatins and its application in the synthesis of 2-oxindole derivatives spiro-fused to the α-methylene-γ-butyrolactone functionality

Chemistry - A European Journal

Volumn 20, Issue 35, 2014, Pages 11091-11100

  Takahashi, Masaki ^a   Murata, Yusuke ^a   Yagishita, Fumitoshi ^b   Sakamoto, Masami ^b   Sengoku, Tetsuya ^a   Yoda, Hidemi ^a  

^a SHIZUOKA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

allylation; antitumor agents; asymmetric catalysis; lactones; spiro compounds

Indexed keywords

ALLYLATION; AMIDES; CATALYSIS; STEREOCHEMISTRY; SUBSTRATES;

ANTI-TUMOR AGENTS; ANTINEOPLASTIC DRUGS; ASYMMETRIC CATALYSIS; CATALYTIC REACTIONS; HOMOALLYLIC ALCOHOL; HYDROGEN-BOND INTERACTIONS; LACTONES; SPIRO COMPOUNDS;

ENANTIOSELECTIVITY;

EID: 84906781624     PISSN: 09476539     EISSN: 15213765     Source Type: Journal    
DOI: 10.1002/chem.201403357     Document Type: Article

References (67)

1. Y. Yamamoto, N. Asao, Chem. Rev. 1993, 93, 2207-2293
2. Y. Yamamoto, Acc. Chem. Res. 1987, 20, 243-249.
3. K. Tanaka, H. Yoda, Y. Isobe, A. Kaji, J. Org. Chem. 1986, 51, 1856-1866
4. K. Tanaka, H. Yoda, Y. Isobe, A. Kaji, Tetrahedron Lett. 1985, 26, 1337-1340.
5. T. Suzuki, J. Atsumi, T. Sengoku, M. Takahashi, H. Yoda, J. Organomet. Chem. 2010, 695, 128-136
6. T. Suzuki, T. Sengoku, M. Takahashi, H. Yoda, Tetrahedron Lett. 2008, 49, 4701-4703.
7. D. L. Silverio, S. Torker, T. Pilyugina, E. M. Vieira, M. L. Snapper, F. Haeffner, A. H. Hoveyda, Nature 2013, 494, 216-221
8. J. Itoh, S. B. Han, M. J. Krische, Angew. Chem. 2009, 121, 6431-6434
9. Angew. Chem. Int. Ed. 2009, 48, 6313-6316
10. A. K. Franz, P. D. Dreyfuss, S. L. Schreiber, J. Am. Chem. Soc. 2007, 129, 1020-1021
11. B. M. Trost, M. U. Frederiksen, Angew. Chem. 2005, 117, 312-314
12. Angew. Chem. Int. Ed. 2005, 44, 308-310.
13. R. A. Kitson, A. Millemaggi, R. J. K. Taylor, Angew. Chem. 2009, 121, 9590-9615
14. Angew. Chem. Int. Ed. 2009, 48, 9426-9451
15. A. Bachelier, R. Mayer, C. D. Klein, Bioorg. Med. Chem. Lett. 2006, 16, 5605-5609
16. B. Siedle, A. J. García-Piñeres, R. Murillo, J. Schulte-Mönting, V. Castro, P. Rüngeler, C. A. Klaas, F. B. Da Costa, W. Kisiel, I. Merfort, J. Med. Chem. 2004, 47, 6042-6054
17. P. Rüngeler, V. Castro, G. Mora, N. Gören, W. Vichnewski, H. L. Pahl, I. Merfort, T. J. Schmidt, Bioorg. Med. Chem. 1999, 7, 2343-2352.
18. M. Takahashi, T. Sudo, Y. Murata, T. Sengoku, H. Yoda, Nat. Prod. Commun. 2013, 8, 889-896
19. M. Takahashi, J. Atsumi, T. Sengoku, H. Yoda, Synthesis 2010, 3282-3288.
20. Y. Murata, M. Takahashi, F. Yagishita, M. Sakamoto, T. Sengoku, H. Yoda, Org. Lett. 2013, 15, 6182-6185.
21. N. D. Heindel, J. A. Minatelli, J. Pharm. Sci. 1981, 70, 84-86.
22. G. S. Singh, Z. Y. Desta, Chem. Rev. 2012, 112, 6104-6155
23. S. Kato, T. Yoshino, M. Shibasaki, M. Kanai, S. Matsunaga, Angew. Chem. 2012, 124, 7113-7116
24. Angew. Chem. Int. Ed. 2012, 51, 7007-7010
25. C. V. Galliford, K. A. Scheidt, Angew. Chem. 2007, 119, 8902-8912
26. Angew. Chem. Int. Ed. 2007, 46, 8748-8758
27. C. Marti, E. M. Carreira, Eur. J. Org. Chem. 2003, 2209-2219.
28. Q.-L. Wang, L. Peng, F.-Y. Wang, M.-L. Zhang, L.-N. Jia, F. Tian, X.-Y. Xu, L.-X. Wang, Chem. Commun. 2013, 49, 9422-9424
29. S. Rana, A. Natarajan, Org. Biomol. Chem. 2013, 11, 244-247
30. P. Shanmugam, B. Viswambharan, Synlett 2008, 2763-2768
31. P. Shanmugam, V. Vaithiyanathan, Tetrahedron 2008, 64, 3322-3330.
32. Y. Motoyama, O. Kurihara, K. Murata, K. Aoki, H. Nishiyama, Organometallics 2000, 19, 1025-1034
33. H. Nishiyama, H. Sakaguchi, T. Nakamura, M. Horihata, M. Kondo, K. Itoh, Organometallics 1989, 8, 846-848.
34. N. R. Ball-Jones, J. J. Badillo, A. K. Franz, Org. Biomol. Chem. 2012, 10, 5165-5181
35. J. P. MacDonald, J. J. Badillo, G. E. Arevalo, A. Silva-García, A. K. Franz, ACS Comb. Sci. 2012, 14, 285-293
36. E. G. Gutierrez, C. J. Wong, A. H. Sahin, A. K. Franz, Org. Lett. 2011, 13, 5754-5757
37. J. J. Badillo, A. Silva-García, B. H. Shupe, J. C. Fettinger, A. K. Franz, Tetrahedron Lett. 2011, 52, 5550-5553
38. N. V. Hanhan, A. H. Sahin, T. W. Chang, J. C. Fettinger, A. K. Franz, Angew. Chem. Int. Ed. 2010, 49, 744-747.
39. N. V. Hanhan, Y. C. Tang, N. T. Tran, A. K. Franz, Org. Lett. 2012, 14, 2218-2221
40. N. V. Hanhan, N. R. Ball-Jones, N. T. Tran, A. K. Franz, Angew. Chem. 2012, 124, 1013-1016
41. Angew. Chem. Int. Ed. 2012, 51, 989-992.
42. B. H. Shupe, E. E. Allen, J. P. MacDonald, S. O. Wilson, A. K. Franz, Org. Lett. 2013, 15, 3218-3221
43. J. J. Badillo, G. E. Arevalo, J. C. Fettinger, A. K. Franz, Org. Lett. 2011, 13, 418-421.
44. 2=0.1116, GoF=1.228, and Flack absolute structure parameter=0.10(6) for 2582 reflections and 222 parameters.
45. For the absolute stereochemistry of 3 h, the R configuration was assigned to the newly created stereogenic center by comparison of the optical rotation with that reported in the literature (see Ref. [13b]). The opposite stereochemical preference in addition to the observed very low enantioselectivity (25 % ee) can be interpreted in terms of inefficient chirality transfer from the chiral environment at the catalytic center.
46. S. E. Denmark, J. Fu, Chem. Rev. 2003, 103, 2763-2794
47. C.-T. Chen, S.-D. Chao, J. Org. Chem. 1999, 64, 1090-1091
48. J. Beignet, L. R. Cox, Org. Lett. 2003, 5, 4231-4234
49. J. Lu, S.-J. Ji, Y.-C. Teo, T.-P. Loh, Org. Lett. 2005, 7, 159-161.
50. The lower efficiency of the reaction than with the isatin substrates is probably responsible for intrinsic low reactivity of the acyclic ketoamide system, which would be attributed to the greater conformational flexibility. The ee value of P2 was determined by HPLC analysis with the Daicel Chiralpak IF.
51. In the mechanistic studies with the hydrogen-containing additives, it was found that use of imidazole (1.2 equiv) had a detrimental effect on both the reactivity and enantioselectivity of the amide allylation to 3 g. In this case, only a sluggish and incomplete reaction took place over 72 h to result in the formation of 3 g with an isolated yield of 12 % as a completely racemic product.
52. 1H NMR spectroscopic studies allowed us to gain additional insight into the proposed transition-state structure. The details are given in the Supporting Information.
53. 2=0.1120, GoF=1.068, and Flack absolute structure parameter=0.1(3) for 1984 reflections and 155 parameters.
54. H. D. Flack, G. Bernardinelli, Acta Crystallogr. Sect. A 1999, 55, 908-915
55. H. D. Flack, Acta Crystallogr. Sect. A 1983, 39, 876-881.
56. Clearly, one can see that these types of compounds will be more easily accessed by the available amide allylation/lactonization sequence from the respective C5-halogenated isatins.
57. A.-S. Castanet, F. Colobert, P.-E. Broutin, Tetrahedron Lett. 2002, 43, 5047-5048
58. M. C. Carreño, J. L. Garucía Ruano, G. Sanz, M. A. Toledo, A. Urbano, Tetrahedron Lett. 1996, 37, 4081-4084.
59. 2=0.0706, GoF=1.062, and Flack absolute structure parameter=0.020(12) for 3675 reflections and 191 parameters.
60. 2=0.0636, GoF=1.027, and Flack absolute structure parameter=-0.028(18) for 3715 reflections and 192 parameters.
61. 2=0.0740, GoF=1.031, and Flack absolute structure parameter=0.049(6) for 2909 reflections and 217 parameters.
62. 2=0.1052, GoF=1.005, and Flack absolute structure parameter=-0.02(2) for 3532 reflections and 208 parameters.
63. 2=0.1031, GoF=1.108, and Flack absolute structure parameter=0.09(2) for 2988 reflections and 166 parameters.
64. 2=0.0563, GoF=1.039, and Flack absolute structure parameter=0.064(8) for 1717 reflections and 164 parameters.
65. 2=0.1076, GoF=1.081, and Flack absolute structure parameter=0.065(5) for 2109 reflections and 164 parameters.
66. On the basis of these results, the absolute configurations of 4 g-i, which were left unassigned, could be determined to be S by distinct correlations with the chiral HPLC analyses of the corresponding cyclization products with those of the authentic samples of (S)- 6 a-8 a, respectively.
67. D. C. Harrowven, D. P. Curran, S. L. Kostiuk, I. L. Wallis-Guy, S. Whiting, K. J. Stenning, B. Tang, E. Packard, L. Nanson, Chem. Commun. 2010, 46, 6335-6337.